The platelet function substudy of the TRILOGY-ACS trial shows that there is no significant difference between prasugrel and clopidogrel in cardiovascular mortality, myocardial infarction, or stroke outcomes.
via MedWire News
via MedWire News
The India Cardiology 2.0 Medical Social Media Network
No comments:
Post a Comment